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Abstract
Background: The objective of this study was to describe the diagnostic panorama of human transmissible
spongiform encephalopathies across 11 countries.
Methods: From data collected for surveillance purposes, we describe annual proportions of deaths due to
different human transmissible spongiform encephalopathies in eleven EUROCJD-consortium countries over the
period 1993–2002, as well as variations in the use of diagnostic tests. Using logistic models we quantified
international differences and changes across time.
Results: In general, pre-mortem use of diagnostic investigations increased with time. International differences in
pathological confirmation of sporadic Creutzfeldt-Jakob disease, stable over time, were evident. Compared to
their counterparts, some countries displayed remarkable patterns, such as: 1) the high proportion, increasing with
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BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278time, of variant Creutzfeldt-Jakob disease in the United Kingdom, (OR 607.99 95%CI 84.72–4363.40), and France
(OR 18.35, 95%CI 2.20–152.83); 2) high, decreasing proportions of iatrogenic Creutzfeldt-Jakob disease in France,
(OR 5.81 95%CI 4.09–8.24), and the United Kingdom, (OR 1.54 95%CI 1.03–2.30); and, 3) high and stable ratios
of genetic forms in Slovakia (OR 21.82 95%CI 12.42–38.33) and Italy (OR 2.12 95%CI 1.69–2.68).
Conclusion: Considerable international variation in aetiological subtypes of human transmissible spongiform
encephalopathies was evident over the observation period. With the exception of variant Creutzfeldt-Jakob
disease and iatrogenic Creutzfeldt-Jakob disease in France and the United Kingdom, these differences persisted
across time.
Background
Human Transmissible Spongiform Encephalopathies
(HTSE) constitute a group of rare, fatal central nervous
system disorders [1]. A general characteristic of HTSE is
deposition of a pathological isoform (termed prion pro-
tein; PrPSc) of the normal cellular prion protein (PrPC).
Diverse aetiological factors and pathogenic mechanisms
underlie the development of HTSE. The sporadic form of
Creutzfeldt-Jakob disease (sCJD), which is of unknown
aetiology, represents the most common form of HTSE,
with an estimated yearly incidence of 1–1.5 per million
population. An inherited form, caused by mutations in
the gene encoding PrPC (PRNP) is known as familial or
genetic Creutzfeldt-Jakob disease (gCJD), or genetic HTSE
(gHTSE) when other recognized entities are included.
Acquired forms of HTSE, such as iatrogenic Creutzfeldt-
Jakob disease (iCJD) or variant Creutzfeldt-Jakob disease
(vCJD), are caused by exposure to infectious prions, be it
through contaminated medical products (iCJD) or uptake
of bovine spongiform encephalopathy (BSE) prions,
(vCJD) [2,4]. The period 1993–2002 witnessed an histor-
ically exceptional situation, inasmuch as eleven countries
(the EUROCJD consortium) conducted co-ordinated epi-
demiological HTSE surveillance, using harmonised meth-
ods against a rapidly changing medical HTSE background.
New entities, such as vCJD, were identified and reported
in a number of countries [5]. Diagnostic tests were devel-
oped and case definitions modified [6,7] and infrequent
forms of HTSE were documented [8]. The descriptive epi-
demiology of HTSE in these populations, plus time inter-
vals and details about HTSE survival, iCJD and gHTSE
have recently been reported [9-12].
Taking into account that individual countries are facing
country-specific risk factors, the need for a comparison of
national registries and temporal analysis of national sur-
veillance data is imperative, highlighted by recent research
indicating that the incidence of HTSE by aetiological sub-
type varies widely geographically [9,13,14]. The fact that
BSE exposure may result in sCJD-like phenotypes, as sug-
gested by experiments performed on rodents, further
underlines the need for in-depth temporal analysis of
HTSE [15,16]. We analysed variations in defined epidemi-
ological parameters in the EUROCJD-consortium HTSE
cohort over a ten-year period. Through this analysis we
have been able to describe variations in the annual
national panorama of investigations used to evaluate
patients and in aetiological HTSE subtypes over a defined
timeframe, both overall and by country.
Methods
Cases included in this study were those registered in the
national databases of constituent countries of the Euro-
pean Union's and Allied countries' prospective CJD sur-
veillance programme (EUROCJD). National registers
started collecting prospective data in 1979 in Slovakia,
1990 in the UK, 1992 in France, and 1993 in Germany,
Italy, The Netherlands and Australia. Spain followed in
1995, as did Austria and Switzerland in 1996, and Canada
in 1997. In 1993, a standardised protocol was introduced
for diagnosing cases for epidemiological surveillance pur-
poses. After the introduction of a diagnostic test based on
detection of 14.3.3 protein in cerebrospinal fluid (CSF) in
1997, this protocol was updated in 1999. Diagnostic cat-
egories were based on application of shared specific diag-
nostic criteria for HTSE [17,18] adapted from those
originally proposed by Masters and colleagues [19],
updating in 1998 for surveillance purposes diagnostic cri-
teria for sCJD [7,9,20]. The study included all patients
with a diagnosis of probable or definite sCJD, gHTSE,
iCJD or vCJD, who died in the period 1993–2002 and
were reported to their respective national surveillance cen-
tres. All information was centralised in Rotterdam.
The patients from each country' included in the study is
summarised in Table 1. The pooled dataset comprised
4441 patients: sCJD n = 3720 (2461 definite, 1269 prob-
able); gHTSE n = 455; iCJD n = 138; and vCJD n = 128.
Iatrogenic forms were due to dura mater grafts (n = 32),
growth hormone (n = 105) and corneal transplantation
(n = 1).
Whenever possible, all diagnostic investigations were
reviewed by a member of the surveillance system. Infor-
mation on electroencephalogram (EEG) records was
available in 3825 cases. Typical periodic sharp and slow
wave complexes (PSWCs) were deemed to be present
when periodic complexes had a bi- or triphasic morphol-Page 2 of 10
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nous, generalised or lateralised on the EEG and persist for
at least 10 seconds [21]. Cerebral magnetic resonance
imaging (MRI) data was available in 2013 individuals,
and was considered positive for sCJD when high signal
changes were present in striatum [22]. Analysis of results
according to specific pulse sequences used for MRI studies
(such as diffusion weighted imaging) was not undertaken.
Information on 14.3.3 protein in CSF was available in
2890 cases, with 14.3.3 Western blotting was performed
in single, national centres within each country with con-
siderable expertise in the assay [4,7]. Genetic analysis was
performed by sequencing the entire open reading frame of
PRNP and was available for 2967 patients.
While time trends of diagnostic patterns of a group of
entities may refer to a varied type of approaches, in this
paper we describe distributions by year of death and pro-
portions of aetiological HTSE type or diagnostic test used
in clinical workup. Changes across time in HTSE inci-
dence or mortality have been reported in prior papers
[9,18]. Therefore, differences between individual coun-
tries and changes across time were explored here by com-
bining national HTSE death ratios for different diagnostic
categories: 1) for each aetiological subtype of disorder; 2)
for sCJD, by pathological or non-diagnostic confirmation,
i.e., probable/definite ratios; and, 3) for different entities
by available specific diagnostic CSF or genotype informa-
tion. The statistical significance of the variation in distri-
butions was assessed using chi-square statistics. Logistic
regression was used to calculate odds ratios (OR) for each
country compared to the other 10, with adjustment for
age at death and year of death: 1) for specific aetiological
subtypes of disorder versus all remaining HTSE; and 2) for
definite versus probable sCJD. For the purposes of compa-
rability, the vCJD death ratios for the remaining 9 coun-
tries were taken as reference for France and the UK alike.
OR time trends were ascertained by introducing time as a
continuous independent variable in the models. In order
to judge the additional contributions made by EEG pat-
terns and presence of 14.3.3 protein in CSF to sCJD diag-
nosis, and by identification of mutations in PRNP to any
gHTSE diagnosis, we calculated the annual proportions of
positive findings in each of these auxiliary tests in cases
where the corresponding findings in EEG, 14.3.3 protein
test, or family history of HTSE were absence of PSWCS or
negative.
The information used in the paper is grouped and mortal-
ity grouped data for each country is publicly available at
the web at the CJD surveillance unit in Edinburgh. The
study underwent evaluation by the Medical Committee
on Ethics of the Rotterdam Academic Hospital, MEC
127.071/1993/71, and by the Carlos III Institute of
Health Committee on Bioethics, report number Pub-102/
06.
Results
Shown in Figure 1 are graphs depicting the population
under surveillance (Figure 1-a) and annual data in the
EUROCJD consortium countries for major HTSE catego-
ries in terms of number of clinical onsets (Figure 1-a),
number of deaths (Figure 1-b), average age at death (Fig-
ure 1-c), as well as the proportion of HTSE deaths for
which EEG, CSF 14.3.3, cerebral MRI and genotyping
results were available (Figure 1-d). The most remarkable
general feature was that at no period was the death or inci-
dence rate stable from year to year. For most entities, the
highest annual number of HTSE onsets occurred early in
the second half of the observation period (Figure 1-a). The
increase in onsets from 1993 to 1998 was mainly in evi-
dence for vCJD (0 to 18 cases), gHTSE (22 to 47 cases) and
Table 1: Number of cases studied by diagnostic entity and country
Sporadic CJD Variant CJD Iatrogenic 
CJD
Genetic TSE All categories
CJD GSS FFI Insert
Australia 189 - 4 14 4 3 1 215
Austria* 77 - - 9 - 3 1 90
Canada** 169 1 3 7 9 - - 189
France 766 6 82 68 5 6 5 938
Germany 827 - 5 31 8 17 12 900
Italy 544 - 3 94 8 10 3 662
Netherlands 136 - 3 1 - - 2 142
Slovakia 18 - - 41 - - - 59
Spain* 380 - 5 18 - 25 1 429
Switzerland 84 - - 1 - - - 85
UK 530 121 33 11 19 1 17 732
All countries 3720 128 138 295 53 65 42 4441
* Since 1996, including retrospective cases from 1993. ** Since 1998, including retrospective cases from 1994Page 3 of 10
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between onset and death was observable for both sCJD
and other entities at the end of the study period, a finding
consistent with selecting cases by death up to 2002, for
inclusion in a database. While a statistically significant
linear trend for increased average age at death was
observed for sCJD (0.30 95%CI 0.14–0.46 years per year),
and iCJD (1.15 95%CI 0.26–1.95 years per year), no such
trend was suggested for gHTSE or vCJD (Figure 1-c).
The use of ancillary tests, such as MRI, 14.3.3 or genetic
analysis, in diagnosis of HTSE (Figure 1-d) increased with
time up to 2002. Overall, the most frequently used inves-
tigation was the EEG, yet in recent years the use of the CSF
14.3.3 protein analysis increased significantly, attaining
levels comparable to EEG analyses in 2000. While rising
time trends were seen for 14.3.3 tests and MRI, stable val-
ues for PRNP genotyping and decreasing figures for EEG
examination were in evidence.
Annual distribution by HTSE type (Figure 2) changed sig-
nificantly, both overall (p < 0.001) and in the UK, p <
0.001, and France p = 0.009 (Pearson χ2). Furthermore,
country- specific patterns were observable, i.e., an increase
in vCJD in the UK and a decrease in iCJD in France. In the
comparative inter-country analysis focusing on specific
diagnostic groups, remarkable differences in magnitude
and linear time trends were found. Of interest were: 1) an
increase over time in vCJD in the UK (OR 607.99 95%CI
84.72–4363.40; time trend OR 1.21, 95%CI 1.11–1.31),
and France (OR 18.35, 95%CI 2.20–152.83; time trend
OR 1.64 95%CI 1.02–2.62), as against other countries; 2)
a decrease over time in iCJD in France, OR 5.81 95%CI
4.09–8.24; time trend OR 0.84, 95%CI 0.80–0.90), and in
the UK, (OR 1.54 95%CI 1.03–2.30, time trend OR 0.85
95%CI 0.79–0.90); and 3) a high proportion of gHTSE in
Slovakia, (OR 21.82 95%CI 12.42–38.33) and Italy, (OR
2.12 95%CI 1.69–2.68), with stable time trends in both
countries, (OR 0.99 95%CI 0.95–1.03).
Annual histopathological confirmation of sCJD (definite
cases) is depicted in Figure 3. There was considerable var-
iation between individual countries, with proportions of
definite sCJD varying from 100% in Slovakia to as low as
61% in France, 59% in Italy, 57% in Germany and 52% in
Spain. Noteworthy was the annual variation in diagnostic
confirmation of sCJD statistically significant, both overall,
p < 0.001, and for specific countries, such as France, p =
0.007, Germany, p < 0.001, Spain p = 0.002, UK p = 0.038
and Austria (Fisher's exact test, p = 0.019). When compar-
ing national, definite versus probable confirmation ratios,
statistically significant low values were found for Spain
(OR 0.50, 95%CI 0.41–0.62), Germany (OR 0.60
95%0.52–0.70), Italy (OR 0.68 95%CI 0.58–0.81), and
France (OR 0.75 95%CI 0.65–0.88), with no differences
in time trend being identified for the four countries (com-
parative time trend OR 1.00 95%CI 0.98–1.03).
The yearly distribution patterns of diagnostic tests -such as
14.3.3 protein detection in CSF, EEG and genetic analyses
in all HTSE- are shown for all countries in Figure 4. During
the study period, the proportions of definite and probable
sCJD deaths with available EEG results in which PSWCS
were identified were 58% and 73% respectively. The
annual variations proved statistically significant, p <
0.001 in both cases, suggesting a rising time trend in atyp-
ical EEG patterns in sCJD since 1997. The proportions of
definite and probable sCJD with 14.3.3 tests were 62%
and 74% respectively for the whole period; annual varia-
tion was not statistically significant, with 88% and 95% of
such tests proving positive. Genetic analyses were per-
formed on 64% of all HTSE. Mutations could be detected
in 8.5% of all HTSE (7.04% missense mutations, 1.04%
insert mutations). The annual proportion of methionine
homozygous cases in PRNP 129 codon for all genetically
examined HTSE patients did not vary significantly, p =
0.116.
The annual proportions of probable sCJD cases having
exclusively positive EEG or 14.3.3 test results, along with
the proportion of gHTSE identified by genetic analysis
only (without family history of prion diseases) are listed
in Table 2. The annual proportion of probable sCJD solely
having a positive EEG declined evenly with time, from
95% to 3% across the period. Up to 1998, few probable
sCJD cases solely had a positive 14.3.3 test (diagnostic cri-
teria changed in 1998), but in that year the annual
number rose sharply, after which it fell slightly to remain
at a mean proportion of 46%. The annual proportion of
gHTSE identified by mutation alone was fairly stable over
the study period, with a mean of 51%.
Discussion
In terms of case numbers, this study constitutes the larg-
est-scale observation of HTSE ever conducted. Prior
reports on this clinical population are sparse [10]. Taking
into account that neither mortality of HTSE nor popula-
tion denominators are considered in this study, the results
suggest that: 1) the panorama of HTSE, as seen from
deaths for all or part of the 1993–2002 period in 11 coun-
tries, varies within and between countries, sometimes
exhibiting characteristic features; 2) there is an expected,
overall rising time trend in annual deaths and proportions
of patients studied using ancillary tests other than EEG; 3)
characteristic national patterns, as seen from the magni-
tude of and time-trends for proportions of specific enti-
ties, were particularly relevant in the UK and France for
vCJD and iCJD, and in Slovakia and Italy for gHTSE; 4)
pathological confirmation of sCJD varied but interna-
tional differences persisted across time; and, 5) the addi-Page 4 of 10
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decreased to almost nil for EEG, increased to stable figures
for the 14.3.3 test, and was high and stable across time for
genetic assay insofar as gHTSE was concerned. The inter-
pretation of these results is complicated by several param-
eters, due to the fact that use of methods for diagnosing
HTSE, particularly CSF 14.3.3 test and MRI, improved sig-
nificantly over the course of the study period.
The eligibility of cases for this study based on vital status
after death proved most appropriate, since diagnostic cri-
teria for probable sCJD may require measurement of dis-
ease duration, <2 years, and quality of diagnosis is
frequently determined by post-mortem examination.
Diagnosis classification for probable cases is therefore nei-
ther conditional to a specific disease course nor provisory.
A rising time-trend in sCJD incidence or mortality has
been observed over the last decade in Austria, France, Ger-
many, Italy, Switzerland, the UK, and other countries
[9,23-25] and has mainly been attributed to progressive,
persistent, improvement in sCJD diagnostic ascertain-
ment [26, 27] or has gone unexplained [9]. This large
dataset makes the EUROCJD countries the most stable ref-
erence population for comparing HTSE incidence, e.g.,
that of sCJD in specific age-groups. Nonetheless, under-
counts due to poor reporting or case ascertainment before
1998, likely due to different awareness and clinical man-
agement of dementia prior to 14.3.3 CSF test, and incom-
plete case-finding after 2001 by observation at death,
suggest that the optimal time interval for incidence meas-
urements using this material should be carefully selected,
e.g., 2000–2001 for sCJD.
Variation across time for four major HTSE groupsFigure 1
Variation across time for four major HTSE groups in: a) annual number of cases by year of clinical onset, with study population 
shown in millions; b) annual number of cases by year of death; c) annual average age at death and; d) proportion of cases, all 
entities, for whom diagnostic data were available in terms of EEG, 14.3.3 test in CSF, MRI and genotyping, by year of death
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presence of vCJD in the UK and France are most remarka-
ble. Abrupt changes in 1997 and 1998 for sCJD suggest a
strong impact of the first vCJD report [4] on diagnostic
practices and the updating of diagnostic criteria. Yet, inter-
pretation of comparative linear time trends can some-
times prove problematic. For instance, changes in average
age at death might reflect improved ascertainment for
sCJD and an exposure-related cohort effect with increas-
ing duration of incubation period for iCJD.
Changes across time reported here may, among other
things, reflect clinical management and reporting, and
variations in pre- and post-mortem laboratory diagnostic
practices and diagnostic criteria updates. The increasing
use of MRI might explain rising trends for CJD since spe-
cific patterns of abnormality on diffusion-weighted and
fluid-attenuated inversion recovery images are highly sen-
sitive and specific for CJD [28]. In EUROCJD countries,
the use by clinicians of the 14.3.3 protein test in sCJD
diagnosis first became significant in 1997. Accordingly,
the 14.3.3 protein in CSF, identified for the not inconsid-
erable annual proportions of HTSE patients who died
from 1993 to 1996 (Figure 1, bottom right) -with test
results shown for definite and probable sCJD (Figure 4,
centre) and probable sCJD (Table 2)- should have been
determined post-mortem, in most cases on frozen CSF
stored for research purposes. This policy might have had:
a) positive effects, in terms of increasing the average
amount of information per registered HTSE case, some-
thing that is particularly interesting for definite sCJD cases
with date of death prior to 1998; and b) bias in research,
due to inclusion of 14.3.3-test results in the database for
probable sCJD being made conditional upon the presence
Annual distribution by type of HTSE in eleven countriesFigure 2
Annual distribution by type of HTSE in eleven countries. Different study intervals for the period, 1993–2002.
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Annual proportion of histopathologically-confirmed sporadic CJDFigure 3
Annual proportion of histopathologically-confirmed, i.e. definite, sporadic CJD in EUROCJD countries.
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Table 2: Additional contribution of: positive results in EEG and CSF examination (14.3.3 protein test) to diagnosis of probable sporadic 
CJD; and identified PrP gene mutation to diagnosis of genetic HTSE.
Year of death Cases solely with positive EEG
Number and percentage of probable 
sporadic CJD cases
Cases solely with positive CSF 14.3.3 test
Number and percentage of probable 
sporadic CJD cases
Cases with mutation and negative or 
missing data on family history.
Number and percentage of genetic TSE 
cases
1993 52 (95) - 13 (48)
1994 60 (70) 7 (8) 16 (50)
1995 61 (68) 4 (4) 15 (45)
1996 62 (64) 13 (14) 23 (55)
1997 30 (30) 21 (21) 20 (53)
1998 32 (18) 65 (36) 26 (55)
1999 15 (9) 67 (38) 24 (49)
2000 11 (6) 79 (41) 23 (40)
2001 8 (5) 95 (58) 30 (44)
2002 4 (3) 69 (54) 40 (65)
BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278of PSWCs in EEG, a requisite for such diagnosis before
1998. The study of associations similar to those reported
[29, 30, 31] using this large database may benefit from
stratification by period of death or diagnostic criteria for
probable sCJD.
Identifying a time-related increase in sCJD incidence in
populations with valine in PRNP codon 129 which have
been considerably exposed to BSE has been a key goal of
EUROCJD-sponsored public health HTSE surveillance,
reinforced by results of recent laboratory research [15,16].
The frequent lack of PRNP codon 129 data for age-specific
national populations makes it impossible to calculate the
incidence figures required as denominators for such anal-
yses. Hence, a surrogate index is currently used, compar-
ing proportions of sCJD with a valine allele in the UK
versus those in other countries and their changes across
time [31]. Our study results for the general population
suggest that there have been no changes over time in this
proportion since 1996 (Figure 4, bottom right). Due to
frequent atypical clinical features [32], probable sCJD is
particularly liable to being misdiagnosed in patients with
valine in codon 129, and as a result expected improve-
ment in sCJD diagnosis internationally is not reflected as
a trend. Monitoring international changes across time in
clinical-geno-phenotype with this extensive and unique
Annual distribution of positive results in ancillary testsFigure 4
Annual distribution of positive results in EEG and 14.3.3 protein tests in sCJD, and for all HTSE, PRNP mutations identified (in 
patients who had and had not been genetically studied) and PRNP codon 129 genotype.
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BMC Public Health 2006, 6:278 http://www.biomedcentral.com/1471-2458/6/278material might require stratification by variables poten-
tially associated with misdiagnosis and codon 129 struc-
ture, e.g., EEG pattern.
Conclusion
This study reveals remarkable international differences in
the HTSE panorama that change with time, as seen from
deaths in eleven countries in the period 1993–2002.
Knowledge of possible biases in the study cohort is vital
for future applications of this dataset, both in clinical/epi-
demiological research and in public health surveillance.
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